In addition, a study by Wanget al. in a scleroderma model has also shown the ability of intraperitoneal metformin to dose dependently reduce IL-17A levels and RORγt expression and increase FOXP3 mRNA expression28. This evidence concerns the gene IL17A and scleroderma.